Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

TUSTIN, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that researchers presented positive data on progress in its federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF viruses and virally infected cells and increase survival in a model of lethal VHF infection. The data were presented at the 2009 Chemical and Biological Defense Science and Technology (CBD S&T) Conference in Dallas, Texas.

Researchers presented interim data from Peregrine's multi-year program to assess the company's PS-targeting antibodies as broad-spectrum agents for the treatment of viral hemorrhagic fevers, a potential biodefense threat. The studies evaluated the activity of Peregrine's PS-targeting antibodies against representatives of major VHF virus families. In these studies, researchers confirmed broad spectrum PS-targeting antibody binding to VHF viral particles and also demonstrated that Peregrine's PS-targeting antibodies bind to mammalian cells infected with hemorrhagic fever viruses. Initial pharmacokinetic and dosing studies also showed that the PS-targeting antibodies are sustainable in the blood at therapeutically relevant concentrations.

Importantly, initial antiviral efficacy studies reported at the conference were encouraging, showing that a single dose of a PS-targeting antibody increased the survival of hamsters infected with lethal doses of viruses from two different VHF virus families. Based on these positive findings, additional efficacy studies, including repeat dose and combination therapy studies, are now underway.

Dr. Amy Brideau-Andersen, head of Peregrine's preclinical antiviral program and lead author of the studies presented at the CBD S&T Confere
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... 26, 2015 , ... Maine Standards Company, LLC is pleased ... kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin B12 in a ... recommended “equal delta” method for linearity testing and is liquid, ready-to-use. Simply add ...
(Date:7/24/2015)... , July 24, 2015 Ryan & ... filed in United States District Court for the Northern District ... persons or entities that purchased the common stock of Avalanche ... between July 31, 2014 and June 15, 2015, inclusive (the ... September 8, 2015, move the Court for appointment as a ...
(Date:7/24/2015)... YORK , July 24, 2015 ... following equities: PDL BioPharma Inc. (NASDAQ: PDLI ), ... (NASDAQ: STEM ), Northwest Biotherapeutics Inc. (NASDAQ: ... ). Free research report on PDL BioPharma can be ... 2015, the NASDAQ Composite ended at 5,146.41, down 0.49%, ...
(Date:7/24/2015)... DIEGO , July 24, 2015 Orexigen ... and financial results for the second quarter 2015 on ... announcement, Orexigen will provide a business update and discuss ... call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... by phone by calling (800) 447-0521 (domestic) or (847) ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... to Plan Next Clinical StudiesOMAHA, Neb. and HOUSTON, ... TBIO) and Power3 Medical Products, Inc. (OTC Bulletin ... NuroPro(R) AD and NuroPro(R) PD tests for Alzheimer,s ... of Neurology meeting in Seattle, WA. The NuroPro ...
... May 11 NanoLogix, Inc. (Pink Sheets: NNLX) is ... Board to help evaluate and target research and development ... the company with a vastly expanded scope of expertise ... NanoLogix cofounder and author of numerous NanoLogix patents, has ...
... HIV Vaccine Panel DiscussionATLANTA, May 11 , WHAT: ... publicly traded biopharmaceutical company developing human, ... (Human Immunodeficiency, Virus) ... the future and plans to expand preventative trials, currently ...
Cached Biology Technology:Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 2Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 3Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 4Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimer's and Parkinson's Diseases at AAN Annual Meeting 5A Global View: NanoLogix Creates Science Advisory Board 2A Global View: NanoLogix Creates Science Advisory Board 3A Global View: NanoLogix Creates Science Advisory Board 4A Global View: NanoLogix Creates Science Advisory Board 5
(Date:7/8/2015)... CORAL SPRINGS, Florida , July 8, 2015 ... is constantly evolving as this summer,s must have products such ... high in demand as popularity for biometrics based devices continues ... today are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. ... Fitbit Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
Breaking Biology News(10 mins):Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... Duke University Medical Center researchers have created a three-dimensional ... physicians to repair damaged joints with the patient's own ... scaffold could be used in clinical trials within three ... in the Orthopedic Bioengineering Laboratory who designed and built ...
... Researchers have found evidence that rats are capable of ... cognitive states. This ability, which can also be thought ... one's own mental processes, was previously only recognized in ... Allison Foote and Jonathon Crystal of the University of ...
... the overall cost of patients' time spent on cancer care was ... new study in the January 3 issue of the Journal ... 11 cancers studied and for different phases of cancer care varied ... medical costs of cancer care, but few have attempted to include ...
Cached Biology News:Woven scaffolds could improve cartilage repair 2Metacognition: Faced with a test, rats can check their knowledge first 2Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3